Lotus Apothecary Project Alleviate combines modern biotechnology, molecular
biology including holistic milieu therapy, and ancient biological medicine.
Lotus Apothecary Project Alleviate develops their primary products based on viral vaccines and
peptides. Additionally Lotus Apothecary Project Alleviate will offer custom development and
custom manufacturing services both to pharmaceutical and medical institutions.
The major input comes from Dr. Pearl Laperla, USA, founder and CEO of Lotus
Apothecary Project Alleviate. This unique constellation results from the incorporation of the interesting
theories of Antoine Bechamp(1816-1908) and Professor Dr. Gunther Enderlein
(1872-1968), and the knowledge of the ancient, natural medicine, particularly
the Ayurvedic Medicine.
The major product lines and their potential fields of application within the
manufacturing part of LAPA are shown in Fig. 1.
Fig. 1: Current product line of
LAPA Product Line
||Drug candidates deducted from inactivated viruses,
Infections like hepatitis, herpes, malignant melanoma, Non-Hodgkin
disease, prostate, mumps, lung, stomach, or colon cancer, etc.
|Viral Vector Vaccines
||Immune infections like HIV
|Modified Peptides (Lanthionines)
Lanthionine Bridged Peptides
Heavy pain treatment (to substitute Morphine)
Restores skin and tissue